Current Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 54)
Current Health logo

Current Health

ChallengerHealthcare

Remote Patient Monitoring & Hospital-at-Home Platform

Current Health is a remote patient monitoring platform re-acquired by co-founder Christopher McGhee from Best Buy in mid-2025 after Best Buy paid $400M for it in 2021;

AI VisibilityBeta
Overall Score
C54
Category Rank
#210 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
50
Gemini
56

About

Current Health is a remote patient monitoring (RPM) and hospital-at-home technology company originally founded in Edinburgh, Scotland, and later headquartered in the United States. The platform integrates wearable vital sign monitors, connected medical devices, telehealth, and patient engagement tools into a unified care delivery system that enables healthcare providers to remotely monitor and manage patients with chronic conditions, acute illness, or post-surgical needs from their own homes. Current Health's platform connects patient-generated health data in real time to clinical care teams through HIPAA-compliant infrastructure, with integrations into major electronic health record (EHR) systems.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

54
Overall Score
90
#210
Category Rank
#2
75
AI Consensus
83
stable
Trend
stable
59
ChatGPT
92
50
Perplexity
93
56
Gemini
89
49
Claude
96
53
Grok
95

Key Details

Category
Remote Patient Monitoring & Hospital-at-Home Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.